Sarepta Therapeutics, Inc.
SRPT- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0000873303
No open-market purchases or sales by Sarepta Therapeutics, Inc. insiders were filed in the last 90 days; 326 institutions reported holding it in 13F filings for Q2 2026, worth $1.93B in total; no superinvestor holds it.
Key figures
- Market capClose on Nov 13, 2026
- $1.72B
- Insider buysOpen market, last 90 days
- 0
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, −17 vs. previous quarter
- 326
- 13F valueReported value at the end of Q2 2026
- $1.93B
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2025
- $2.20B
- +15.6% year over year
- Net income, FY2025
- -$713.4M
- −403.3% year over year
- Free cash flow, FY2025
- -$307.5M
- No comparable prior period
- Revenue, Q3 FY2026
- $381.4M
- −4.5% year over year
Revenue flow, FY2025
Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue.
Net loss for FY2025: $713.4M (32.5% of revenue).
Short interest
See short dataFrom FINRA, settlement date Oct 30, 2026.
- Short interest
- 19.3M
- Shares sold short
- Change
- −3.03M
- −13.6% vs. previous
- Days to cover
- 7.82
- At average daily volume
Superinvestors holding SRPT, Q2 2026
Go to the superinvestors tabNo superinvestor reported holding SRPT at the end of Q2 2026.
Latest insider trades
See all insider tradesOpen-market purchases and sales by Sarepta Therapeutics, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Mar 13, 2026 (view filing) | Mar 12 | 1 day | Mayo StephenDirector | SSale | −7.24K | $17.02 | −$123.2K | −80.4%1.76K after | |
| Dec 18, 2025 (view filing) | Dec 16 | 2 days | Estepan Ian MichaelChief Operating Officer | SSale | −13.2K | $22.31 | −$294.2K | −6.4%193.3K after | |
| Mar 13, 2025 (view filing) | Mar 12 | 1 day | Nicaise ClaudeDirector | SSale | −2.49K | $99.64 | −$248.2K | −8.2%27.8K after | |
| Dec 16, 2024 (view filing) | Dec 12 | 4 days | Wigzell Hans Lennart RudolfDirector | SSale | −10.5K | $124.84 | −$1.31M | −31.5%22.8K after | |
| Dec 6, 2024 (view filing) | Dec 5 | 1 day | Boor Kathryn JeanDirector | SSale | −1.64K | $125.55 | −$205.4K | −21.8%5.88K after | |
| Sep 3, 2024 (view filing) | Aug 30 | 4 days | Estepan Ian MichaelChief Financial Officer | SSale | −5.99K | $137.36 | −$822.1K | −15.0%33.9K after | |
| Aug 20, 2024 (view filing) | Aug 16 | 4 days | Chambers Michael AndrewDirector | PPurchase | +37.0K | $133.80 | +$4.96M | +15.0%284.0K after | 3 lots |
| Jun 25, 2024 (view filing) | Jun 25 | Same day | Brown Ryan EdwardEVP, General Counsel | SSale | −39.0K | $161.61 | −$6.30M | −69.5%17.1K after | 7 lots10b5-1 |
| Jun 25, 2024 (view filing) | Jun 24-25 | 1 day | Arif BilalChief Tech Ops Officer | SSale | −11.8K | $163.13 | −$1.92M | −40.4%17.4K after | 6 lots10b5-1 |
| May 6, 2024 (view filing) | May 2 | 4 days | Murray DallanChief Customer Officer | SSale | −3.63K | $140.00 | −$508.9K | −16.7%18.1K after | 10b5-1 |
Top 10 13F holders, Q2 2026
See all 326 holdersThe largest institutional positions in Sarepta Therapeutics, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| BlackRock, Inc. | 18,994,958 | $341.3M | 0.01% | +4,239,681+28.7% | Added |
| State Street Corp | 8,916,090 | $160.2M | 0.00% | +2,302,776+34.8% | Added |
| Vanguard Portfolio Management LLC | 8,377,470 | $150.5M | 0.01% | +1,736,778+26.2% | Added |
| Two Sigma Investments, LP | 4,598,735 | $82.6M | 0.06% | +5,540+0.1% | Added |
| Vanguard Capital Management LLC | 4,591,755 | $82.5M | 0.00% | +13,520+0.3% | Added |
| First Trust Advisors LP | 4,365,951 | $78.5M | 0.05% | +230,163+5.6% | Added |
| AQR Capital Management LLC | 4,325,689 | $76.9M | 0.03% | −2,107,423−32.8% | Reduced |
| Geode Capital Management, LLC | 2,771,758 | $49.8M | 0.00% | +782,962+39.4% | Added |
| Erste Asset Management GmbH | 2,568,945 | $45.5M | 0.35% | −400,000−13.5% | Reduced |
| Marshall Wace, LLP | 2,206,022 | $39.6M | 0.03% | +1,480,954+204.3% | Added |
Holders of 5% or more of SRPT
See all 4 holders and filingsHolders whose latest Schedule 13D or 13G filing reports 5% or more of Sarepta Therapeutics, Inc..
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| BlackRock, Inc. | 13G/A | 15.80%16.6M shares | +3.20 ppfrom 12.60% | Jan 21, 20262 filings | Jul 30, 2026 | SEC |
| Vanguard Portfolio Management LLC | 13G/A | 8.05%8.50M shares | +1.62 ppfrom 6.43% | Apr 29, 20262 filings | Jul 31, 2026 | SEC |
| State Street Corp | 13G | 7.00%7.41M shares | −1.40 ppfrom 8.40% | Nov 10, 20253 filings | Nov 10, 2026 | SEC |
| Vanguard Capital Management LLC | 13G | 5.11%5.37M shares | New | Apr 30, 20261 filing | Apr 30, 2026 | SEC |
Politician trades
All politician trades in SRPT3 members of Congress reported 11 trades in Sarepta Therapeutics, Inc. since 2020. Newest filings:
| Filed | Politician | Type | Amount |
|---|---|---|---|
| May 6, 2025 | Gilbert Ray Cisneros, Jr. House · CA | Sell | $1K-$15K |
| Aug 21, 2023 | Josh Gottheimer House · NJ | Buy | $1K-$15K |
| Jul 11, 2023 | Josh Gottheimer House · NJ | Sell | $1K-$15K |
| May 19, 2023 | Daniel S. Goldman House · NY | Sell | $15K-$50K |
| Apr 20, 2023 | Josh Gottheimer House · NJ | Buy | $1K-$15K |

House · CA · May 6, 2025
Sell$1K-$15K

House · NJ · Aug 21, 2023
Buy$1K-$15K

House · NJ · Jul 11, 2023
Sell$1K-$15K

House · NY · May 19, 2023
Sell$15K-$50K

House · NJ · Apr 20, 2023
Buy$1K-$15K